The license will enable MMJ to extract active pharmaceutical ingredients from the cannabis plant to manufacture gelcap medications and supply pharmaceutical-grade medicines for its studies which have been approved by the U.S. Food and Drug Administration.
The license includes MMJ 001, a cannabidiol (CBD) derivative for MS, and MMJ-002, a CBD derivative for Huntington’s.
”MMJ is in the process of securing orphan [drug] designation for our lead product, MMJ 001, a cannabidiol (CBD) derivative, for multiple sclerosis in the U.S.,” Tim Moynahan, MMJ BioScience’s chairman, said in a press release.
“MMJ BioScience also plans to repeat that accomplishment for MMJ-102 for Huntington’s disease,” he said.
“The FDA’s granting of orphan designation for multiple sclerosis is a key step toward that goal. These are debilitating diseases that need new